Sam is an Associate in RTW's New Ventures group. She is responsible for evaluating therapeutics for genetically defined diseases as part of both RTW’s venture and asset selection arms.
Prior to joining RTW, Sam was an Alzheimer’s Association Research Fellow at NYU School of Medicine, where she paired genomics with electrophysiology to better elucidate the etiology of neurodegenerative disease. Her doctoral work, published in Nature and Cell Stem Cell, demonstrated epidermal stem cells retain an epigenetic memory of inflammatory encounters marking them as bona fide contributors to innate immune memory. She is the recipient of numerous awards including the Regeneron Prize for Creative Innovation.
Sam received her PhD in Cell Biology and Development from the Rockefeller University, a BS in Molecular Biology with a minor in Chemistry and a BA in History from the University of Pittsburgh.
My passion for understanding disease biology in the hopes of identifying new medicines fueled my benchwork, and I feel privileged to continue this effort alongside such a remarkable team of scientist-investors.